Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

521
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
521
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

579
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
579
Altered States of Awareness01:06

Altered States of Awareness

908
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
908
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

752
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
752
Drug Therapy01:28

Drug Therapy

202
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
202
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

729
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
729

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.

BJPsych open·2026
Same author

Should lamotrigine be discontinued before TMS treatment: A report of three cases.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.

BJPsych open·2026
Same author

Breaking the Silence on Genocide in Gaza: Kudos from Jewish Health Professionals.

Canadian journal of occupational therapy. Revue canadienne d'ergotherapie·2026
Same author

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial.

Pilot and feasibility studies·2025
Same author

Ethical and legal considerations of artificial intelligence applications in psychiatric violence risk assessment: A scoping review protocol.

PloS one·2025

Related Experiment Video

Updated: Dec 27, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.4K

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Daniel Rosenbaum1, Cory Weissman1, Thomas Anderson2

  • 1Psychiatry, University of Toronto Faculty of Medicine, Toronto, Canada.

Journal of Psychopharmacology (Oxford, England)
|February 29, 2020
PubMed
Summary

Psychedelic microdosing is gaining attention, but research is limited. This study found microdosers were less likely to have substance use or anxiety disorders but more likely to use recreational substances.

Keywords:
LSDPsychedelicsmicrodosingpsilocybinsubstance use

More Related Videos

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.5K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

712

Related Experiment Videos

Last Updated: Dec 27, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

7.4K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.5K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

712

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Microdosing psychedelics, consuming sub-hallucinogenic doses, is increasingly popular but poorly understood.
  • Limited data exists on the psychiatric profiles of individuals who practice psychedelic microdosing.

Purpose of the Study:

  • To characterize the practices and demographics of psychedelic microdosers.
  • To investigate psychiatric diagnoses and substance use patterns among microdosers.
  • To establish a foundation for future clinical research on microdosing.

Main Methods:

  • An anonymous online survey was completed by 909 participants recruited from Reddit.
  • Respondents reporting microdosing (LSD or psilocybin) were compared to non-microdosers.
  • Exploratory odds ratio testing analyzed demographic variables, psychiatric diagnoses, and recreational substance use.

Main Results:

  • Microdosers typically used LSD or psilocybin on a one-day-on, two-days-off schedule.
  • Microdosers showed lower odds of past substance use disorders (OR=0.17) and anxiety disorders (OR=0.61).
  • Microdosers reported higher odds of recent recreational substance use (OR=5.2).

Conclusions:

  • Further research is needed to understand the characteristics of psychedelic microdosers.
  • Randomized controlled trials are essential to assess the safety and efficacy of microdosing.
  • Clinical studies are required to validate reported benefits and tolerability in patient populations.